Sector News

GSK seeks mid-Sept bids for $4 billion Indian Horlicks unit: sources

August 22, 2018
Life sciences

GlaxoSmithKline is seeking initial bids by mid-September for its India-focused Horlicks health nutrition business, which is expected to fetch more than $4 billion, two people familiar with the situation said on Tuesday.

The British drugmaker started a strategic review of Horlicks – a malt-based drink brand popular in India – and some smaller products, after buying Novartis out of their consumer healthcare venture for $13 billion in March.

Potential acquirers are likely to include major food and consumer products groups, such as Nestle, Pepsico and Reckitt Benckiser, the sources said.

The large Indian consumer business could also be of interest to other food and drink companies.

GSK, Nestle and Reckitt declined to comment, while officials at Pepsico were not immediately available. The timing of the bidding process was first reported by Bloomberg.

The main asset on the block in the sale is GSK’s 72.5 percent stake in its Indian subsidiary GlaxoSmithKline Consumer Healthcare, which is famous for Horlicks but also makes other products, including the chocolate-flavoured malt-based drink Boost.

Horlicks is more than 140 years old with origins dating back to 1873, when two British-born men, James and William Horlick, founded a company in Chicago to manufacture the drink. It was introduced to India by Indian soldiers who had fought with the British Army in the First World War.

Nestle, the world’s biggest packaged food company, has previously told GSK privately of its interest in Horlicks on several occasions, people familiar with the matter told Reuters earlier this year. Nestle already owns the malt drink Milo, but it is not a big seller in India.

GSK is being advised by Morgan Stanley and Greenhill.

By Ben Hirschler, Pamela Barbaglia and Martinne Geller

Source: Reuters

Related News

April 17, 2021

Thermo Fisher to buy research contractor PPD in $17B deal

Life sciences

Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.

April 17, 2021

Nestlé finds supplement cocktail slashes preterm birth in major preconception study

Life sciences

Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.

April 17, 2021

Eli Lilly, riding pharma’s rising digital wave, drafts Apple exec to replace Shah as CDO

Life sciences

Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.

Send this to a friend